|
IL112969A
(en)
*
|
1994-03-17 |
2001-05-20 |
Baxter Int |
Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator
|
|
US6143292A
(en)
*
|
1995-05-25 |
2000-11-07 |
Baxter International Inc. |
Allogeneic cell therapy for cancer following allogeneic stem cell transplantation
|
|
US5800539A
(en)
*
|
1995-11-08 |
1998-09-01 |
Emory University |
Method of allogeneic hematopoietic stem cell transplantation without graft failure or graft vs. host disease
|
|
US6805861B2
(en)
*
|
1996-01-17 |
2004-10-19 |
Imperial College Innovations Limited |
Immunotherapy using cytotoxic T lymphocytes (CTL)
|
|
US6213127B1
(en)
|
1996-07-29 |
2001-04-10 |
Emory University |
Methods for treating cancer using allogeneic lymphocytes without graft vs host disease activity
|
|
US5834487A
(en)
*
|
1996-09-24 |
1998-11-10 |
Cv Therapeutics |
Inhibition of 26S and 20S proteasome by indanones
|
|
IL129573A0
(en)
*
|
1996-11-15 |
2000-02-29 |
Baxter Int |
Conditioning for allogeneic stem cell transplantation
|
|
US6428782B1
(en)
*
|
1997-05-23 |
2002-08-06 |
Hadasit Medical Research Services And Development Ltd. |
Non-myeloablative tolerogenic treatment
|
|
AU9589398A
(en)
*
|
1997-10-10 |
1999-05-03 |
Applied Immunotherapeutics, Inc. |
Cancer immunotherapy using allostimulated cells in a multiple sequential implantation strategy
|
|
US20040033230A1
(en)
*
|
1997-12-24 |
2004-02-19 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of breast cancer
|
|
US7598226B2
(en)
|
1998-12-28 |
2009-10-06 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of breast cancer
|
|
US6969518B2
(en)
*
|
1998-12-28 |
2005-11-29 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of breast cancer
|
|
AU1807401A
(en)
*
|
1999-11-30 |
2001-06-12 |
Corixa Corporation |
Compositions and methods for therapy and diagnosis of breast cancer
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
US7541184B2
(en)
|
2000-02-24 |
2009-06-02 |
Invitrogen Corporation |
Activation and expansion of cells
|
|
JP4917201B2
(ja)
*
|
2000-12-04 |
2012-04-18 |
株式会社リンフォテック |
臍帯血移植後の腫瘍および各種感染症の予防・治療用製剤、臍帯血移植後の移植臍帯血幹細胞の生着促進用製剤、臍帯血移植後の腫瘍および各種感染症の予防・治療用製剤ならびに臍帯血移植後の移植臍帯血幹細胞の生着促進用製剤の製造方法。
|
|
KR20020060643A
(ko)
*
|
2002-06-04 |
2002-07-18 |
김진경 |
타인의 면역시스템을 이용하는 암의 치료 방법
|
|
ES2422193T3
(es)
*
|
2002-06-28 |
2013-09-09 |
Life Technologies Corp |
Métodos para restaurar el repertorio inmune en pacientes con defectos inmunológicos relacionados con la autoinmunidad y trasplante de órganos o de células madre hematopoyéticas
|
|
US20050084967A1
(en)
|
2002-06-28 |
2005-04-21 |
Xcyte Therapies, Inc. |
Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
|
|
US20040175373A1
(en)
*
|
2002-06-28 |
2004-09-09 |
Xcyte Therapies, Inc. |
Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
|
|
WO2005021734A2
(en)
*
|
2003-09-02 |
2005-03-10 |
University Of Massachussets |
Generation of hematopoietic chimerism and induction of central tolerance
|
|
CA2555841A1
(en)
*
|
2004-02-12 |
2005-09-01 |
Nektar Therapeutics |
Interleukin-13 antagonist powders, spray-dried particles, and methods
|
|
WO2006004592A2
(en)
*
|
2004-05-28 |
2006-01-12 |
Mayo Foundation For Medical Education And Research |
Methods for autologous stem cell transplantation
|
|
US9155789B2
(en)
*
|
2005-04-25 |
2015-10-13 |
New York University |
Use of allogenic or syngenic major histocompatibility complex (MHC) molecules as universal adjuvants for vaccines against neoplastic disease, infection and autoimmune disease
|
|
KR20090058512A
(ko)
|
2006-08-04 |
2009-06-09 |
아스트라제네카 아베 |
Ｅｒｂｂ2에 대한 인간 항체
|
|
AU2007281684C1
(en)
|
2006-08-07 |
2013-12-19 |
Abbvie Biotherapeutics Inc. |
Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies
|
|
AU2007281682B2
(en)
|
2006-08-07 |
2013-05-16 |
Abbvie Biotherapeutics Inc. |
Compositions and methods using anti-CS1 antibodies to treat multiple myeloma
|
|
JP2010508854A
(ja)
*
|
2006-11-08 |
2010-03-25 |
アルダジェン， インコーポレイテッド |
幹細胞移植の後の生着を改善するための方法
|
|
CA2668608A1
(en)
*
|
2006-11-08 |
2008-06-05 |
Aldagen, Inc. |
Methods for using aldhbr cells to supplement stem cell transplantation
|
|
CN102596209A
(zh)
*
|
2009-08-17 |
2012-07-18 |
国立大学法人东京大学 |
含有短暂性存活ctl的医药品组合物
|
|
RU2657758C2
(ru)
|
2011-12-22 |
2018-06-15 |
Иеда Рисеч Энд Девелопмент Ко. Лтд. |
Комбинированная терапия для стабильного и долговременного приживления трансплантата
|
|
US10365280B2
(en)
|
2014-10-02 |
2019-07-30 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating malignancies
|
|
WO2016073184A1
(en)
|
2014-11-04 |
2016-05-12 |
Dana Farber Cancer Institute, Inc. |
Compositions and methods for treating multiple myeloma
|
|
CN118662615A
(zh)
|
2017-03-15 |
2024-09-20 |
浩康生物系统公司 |
用于造血干细胞移植的组合物和方法
|
|
US12594341B2
(en)
|
2020-06-14 |
2026-04-07 |
Shimon Slavin |
Multifunctional immunotherapeutic monoclonal antibody complexes and conjugates
|